cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29333917
title: The good, the bad, and the ugly: A qualitative evaluation of web-based COVID-19 vaccine communication in Canada

description: Poor website accessibility and usability with credible website/information sources can create barriers to the equitable uptake of vaccines. Scarce research investigates how intended users interact with and perceive official COVID-19 websites. We examine how people in Canada interact with official COVID-19 vaccine websites and how they use information to inform their choices regarding COVID-19 vaccinations. Using a qualitative design and talk-aloud (also called ‘think-aloud’) method, we conducted interviews with 50 general population individuals residing in 3 provinces in Canada in July-December 2021, during which they navigated specific government websites and attempted to find information on various aspects of COVID-19. During the interviews, participants were given specific tasks (e.g. searching for specific information on the websites) and asked to ‘think aloud’ while performing them. Thematic content was used to identify positive and negative elements regarding the websites that were stated by participants as they navigated the websites. Our analysis demonstrated that participants appreciated websites that featured user-friendly and aesthetically pleasing designs, had local and updated information, offered links to reputable sources, and dispelled misconceptions. Participants also critiqued sites for using technical jargon, presenting seemingly insufficient information, and potentially having conflicts of interest. These findings underline the need for health authorities to prioritize web-based communication and understand the information needs of their audience. Ignoring user preferences raises potential risks of poor communication, such as leaving their citizens seeking information elsewhere.
DOI: 10.6084/m9.figshare.29333917.v1
title: The good, the bad, and the ugly: A qualitative evaluation of web-based COVID-19 vaccine communication in Canada

description: Poor website accessibility and usability with credible website/information sources can create barriers to the equitable uptake of vaccines. Scarce research investigates how intended users interact with and perceive official COVID-19 websites. We examine how people in Canada interact with official COVID-19 vaccine websites and how they use information to inform their choices regarding COVID-19 vaccinations. Using a qualitative design and talk-aloud (also called ‘think-aloud’) method, we conducted interviews with 50 general population individuals residing in 3 provinces in Canada in July-December 2021, during which they navigated specific government websites and attempted to find information on various aspects of COVID-19. During the interviews, participants were given specific tasks (e.g. searching for specific information on the websites) and asked to ‘think aloud’ while performing them. Thematic content was used to identify positive and negative elements regarding the websites that were stated by participants as they navigated the websites. Our analysis demonstrated that participants appreciated websites that featured user-friendly and aesthetically pleasing designs, had local and updated information, offered links to reputable sources, and dispelled misconceptions. Participants also critiqued sites for using technical jargon, presenting seemingly insufficient information, and potentially having conflicts of interest. These findings underline the need for health authorities to prioritize web-based communication and understand the information needs of their audience. Ignoring user preferences raises potential risks of poor communication, such as leaving their citizens seeking information elsewhere.
DOI: 10.6084/m9.figshare.30912979
title: A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination

description: Globally aging demographics necessitate proactive public health interventions like adult immunization programs, but comprehensive estimates of their socioeconomic value are lacking or narrow in perspective, risking suboptimal decision-making. To estimate the socioeconomic value of adult immunization programs for influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus across ten countries. Benefit-cost analysis using static disease models and a reference case framework to quantify net monetary benefits of immunization programs using different monetization approaches for non-monetary benefits. Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, US. Based on the lowest and highest valuations of non-monetary benefits, across all immunization programs, the mean benefit-cost ratios (BCRs) ranged from 5 to 19, suggesting substantial positive returns. Mortality-focused disease programs like influenza (BCRs 6–22) and pneumococcal disease (BCRs 15–33) showed the highest returns. The emerging respiratory syncytial virus program also demonstrated high potential positive returns (BCRs 6–16). Herpes zoster programs which primarily affect quality of life also yielded positive returns with BCRs of 2–4. Across all data points, 95% of estimated BCRs exceeded the cost-neutral 1.0 threshold. Adult immunization programs for influenza, pneumococcal disease, respiratory syncytial virus and herpes zoster consistently show positive returns on investment across a diversity of countries. Funding these programs provides long-term benefits and may help to mitigate upcoming global demographic challenges.
DOI: 10.6084/m9.figshare.30912979.v1
title: A cost-benefit analysis of adult immunization programs across ten countries: Modeling the socioeconomic value of immunization for older populations compared to no vaccination

description: Globally aging demographics necessitate proactive public health interventions like adult immunization programs, but comprehensive estimates of their socioeconomic value are lacking or narrow in perspective, risking suboptimal decision-making. To estimate the socioeconomic value of adult immunization programs for influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus across ten countries. Benefit-cost analysis using static disease models and a reference case framework to quantify net monetary benefits of immunization programs using different monetization approaches for non-monetary benefits. Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, US. Based on the lowest and highest valuations of non-monetary benefits, across all immunization programs, the mean benefit-cost ratios (BCRs) ranged from 5 to 19, suggesting substantial positive returns. Mortality-focused disease programs like influenza (BCRs 6–22) and pneumococcal disease (BCRs 15–33) showed the highest returns. The emerging respiratory syncytial virus program also demonstrated high potential positive returns (BCRs 6–16). Herpes zoster programs which primarily affect quality of life also yielded positive returns with BCRs of 2–4. Across all data points, 95% of estimated BCRs exceeded the cost-neutral 1.0 threshold. Adult immunization programs for influenza, pneumococcal disease, respiratory syncytial virus and herpes zoster consistently show positive returns on investment across a diversity of countries. Funding these programs provides long-term benefits and may help to mitigate upcoming global demographic challenges.
DOI: 10.5281/zenodo.18712987
title: Coexisting Kagome and Heavy Fermion Flat Bands in YbCr6Ge6

description: The file name of "Supplementary_Data_1.txt" is YbCr6Ge6_atomic_coordinates_CIF_POSCAR.
DOI: 10.6084/m9.figshare.28063358
title: Hemostatic changes following COVID-19 vaccination: Do they promote a pro-thrombotic state?

description: Vaccine-induced thrombotic thrombocytopenia (VITT) is a unique thrombotic complication of Coronavirus Disease 2019 (COVID-19) immunization, especially with adenovirus vector vaccines. However, non-VITT thrombotic events were seen in mRNA vaccines. We aimed to investigate hemostatic changes following COVID-19 vaccination, and to compare these changes between the ChAdOx1 and BNT162b2 vaccines. We conducted a prospective study involving COVID-19 infection- and vaccination-naïve participants aged over 18 years receiving the ChAdOx1 or BNT162b2 vaccines. Blood samples were collected at pre-vaccination, 7 and 21 days post-vaccination. D-dimer levels, platelet counts, and TGA parameters were collected. ChAdOx1-S group D-dimer levels did not change significantly throughout the study (<i>p</i> = .51). BNT162b2 group median D-dimer levels increased significantly on day 7 [245 ng FEU/mL (IQR 155–384) at baseline; 315 ng FEU/mL (IQR 187.5–412) at day 7; and 271 ng FEU/mL (IQR 166–400) at day 21; <i>p</i> = .021]. BNT162b2 group platelet counts increased significantly on day 7 (<i>p</i> = .010). TGA parameters in the ChAdOx1-S group decreased significantly in ETP levels (<i>p</i> = .007) and peak concentrations (<i>p</i> = .041) over time while those of the BNT162b2 group were stable (median ETP levels and peak concentrations; <i>p</i> &gt; .05). Mean change in ETP levels from pre-vaccination between the vaccines were significantly different at day 21 (<i>p</i> = .001). No anti-platelet factor 4 antibody positivity or clinical thrombosis occurred. Both vaccines showed low thrombosis risk without increased thrombin generation. However, BNT162b2 vaccine recipients exhibited a temporary inflammatory response, evidenced by a brief rise in D-dimer levels. TCTR20240812005
DOI: 10.6084/m9.figshare.28063358.v1
title: Hemostatic changes following COVID-19 vaccination: Do they promote a pro-thrombotic state?

description: Vaccine-induced thrombotic thrombocytopenia (VITT) is a unique thrombotic complication of Coronavirus Disease 2019 (COVID-19) immunization, especially with adenovirus vector vaccines. However, non-VITT thrombotic events were seen in mRNA vaccines. We aimed to investigate hemostatic changes following COVID-19 vaccination, and to compare these changes between the ChAdOx1 and BNT162b2 vaccines. We conducted a prospective study involving COVID-19 infection- and vaccination-naïve participants aged over 18 years receiving the ChAdOx1 or BNT162b2 vaccines. Blood samples were collected at pre-vaccination, 7 and 21 days post-vaccination. D-dimer levels, platelet counts, and TGA parameters were collected. ChAdOx1-S group D-dimer levels did not change significantly throughout the study (<i>p</i> = .51). BNT162b2 group median D-dimer levels increased significantly on day 7 [245 ng FEU/mL (IQR 155–384) at baseline; 315 ng FEU/mL (IQR 187.5–412) at day 7; and 271 ng FEU/mL (IQR 166–400) at day 21; <i>p</i> = .021]. BNT162b2 group platelet counts increased significantly on day 7 (<i>p</i> = .010). TGA parameters in the ChAdOx1-S group decreased significantly in ETP levels (<i>p</i> = .007) and peak concentrations (<i>p</i> = .041) over time while those of the BNT162b2 group were stable (median ETP levels and peak concentrations; <i>p</i> &gt; .05). Mean change in ETP levels from pre-vaccination between the vaccines were significantly different at day 21 (<i>p</i> = .001). No anti-platelet factor 4 antibody positivity or clinical thrombosis occurred. Both vaccines showed low thrombosis risk without increased thrombin generation. However, BNT162b2 vaccine recipients exhibited a temporary inflammatory response, evidenced by a brief rise in D-dimer levels. TCTR20240812005
DOI: 10.6084/m9.figshare.30366045
title: Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia

description: Understanding health behavior using the Health Belief Model (HBM) helps formulate strategies to improve the willingness, thereby increasing the acceptance of pneumococcal vaccination among the elderly. We aimed to assess the willingness to receive the pneumococcal vaccine and associated factors to inform pneumococcal vaccination policy for the elderly in Malaysia. We surveyed 402 elderly (60 years and above) selected from 14 Pusat Aktiviti Warga Emas (PAWE; Senior Citizen Activity Centers) in Klang Valley, Malaysia. Using a questionnaire, we gathered information on respondents’ sociodemographic characteristics, self-reported knowledge of pneumococcal diseases, behavioral determinants using the HBM, trust in healthcare, trust in vaccines, and willingness to receive the pneumococcal vaccine. The mean age was 66.4 years (SD = 5.6). Only 29% had received at least one dose of pneumococcal vaccine, almost all of whom (93%) had received it before the Hajj or Umrah pilgrimage of Muslims. Mean willingness score was 8.20 (95% CI 8.01–8.39). Multiple linear regression analysis showed that elderly individuals were more willing to receive the pneumococcal vaccine if they perceived the disease as severe, had fewer barriers to vaccination, were influenced by prompts or encouragement to take action, and had greater trust in healthcare providers and the vaccine itself. The survey found low coverage for pneumococcal vaccination. Our findings suggest that improving information about pneumococcal disease, its severity, and the pneumococcal vaccine through health care providers to the elderly and their families would improve willingness to uptake the pneumococcal vaccine.
DOI: 10.6084/m9.figshare.30366045.v1
title: Factors associated with willingness to accept pneumococcal vaccine based on the Health Belief Model among the elderly (≥60 years) living in Klang Valley, Malaysia

description: Understanding health behavior using the Health Belief Model (HBM) helps formulate strategies to improve the willingness, thereby increasing the acceptance of pneumococcal vaccination among the elderly. We aimed to assess the willingness to receive the pneumococcal vaccine and associated factors to inform pneumococcal vaccination policy for the elderly in Malaysia. We surveyed 402 elderly (60 years and above) selected from 14 Pusat Aktiviti Warga Emas (PAWE; Senior Citizen Activity Centers) in Klang Valley, Malaysia. Using a questionnaire, we gathered information on respondents’ sociodemographic characteristics, self-reported knowledge of pneumococcal diseases, behavioral determinants using the HBM, trust in healthcare, trust in vaccines, and willingness to receive the pneumococcal vaccine. The mean age was 66.4 years (SD = 5.6). Only 29% had received at least one dose of pneumococcal vaccine, almost all of whom (93%) had received it before the Hajj or Umrah pilgrimage of Muslims. Mean willingness score was 8.20 (95% CI 8.01–8.39). Multiple linear regression analysis showed that elderly individuals were more willing to receive the pneumococcal vaccine if they perceived the disease as severe, had fewer barriers to vaccination, were influenced by prompts or encouragement to take action, and had greater trust in healthcare providers and the vaccine itself. The survey found low coverage for pneumococcal vaccination. Our findings suggest that improving information about pneumococcal disease, its severity, and the pneumococcal vaccine through health care providers to the elderly and their families would improve willingness to uptake the pneumococcal vaccine.
DOI: 10.5281/zenodo.18712986
title: Coexisting Kagome and Heavy Fermion Flat Bands in YbCr6Ge6

description: The file name of "Supplementary_Data_1.txt" is YbCr6Ge6_atomic_coordinates_CIF_POSCAR.
DOI: 10.6084/m9.figshare.28331142
title: Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy

description: The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. Hence, we conducted a meta-analysis on safety and efficacy of ICIs in cancer patients with preexisting autoimmune diseases to provide further insights. PubMed, EMBASE, and Cochrane Library were systematically searched until December 20, 2024. The main summary measures used were pooled rate and risk ratio (RR) with 95% confidential interval (CI), which were analyzed using R statistic software. A total of 52 articles were included in the study. When cancer patients with preexisting autoimmune diseases received ICIs treatment, the overall incidence was 0.610 (95% CI: 0.531–0.686) for any grade irAEs, 0.295 (95% CI: 0.248–0.343) for flares, 0.325 (95% CI: 0.258–0.396) for de novo irAEs, 0.238 (95% CI: 0.174–0.309) for grade ≥3 irAEs, and 0.143 (95% CI: 0.109–0.180) for discontinuation due to immunotoxicity. Compared with those without autoimmune diseases, cancer patients with autoimmune diseases experienced a higher risk of any-grade irAEs (RR: 1.23, 95% CI: 1.12–1.35) and discontinuation due to immunotoxicity (1.40, 95% CI: 1.11–1.78). However, no statistically significant differences were observed in the incidence of grade ≥3 irAEs, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between the two groups. During ICIs treatment, irAEs are common among cancer patients with autoimmune diseases, but severe irAEs is relatively low. ICIs are effective in this population, but should be strictly monitored when used to avoid immunotoxicity.
DOI: 10.6084/m9.figshare.28331142.v1
title: Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy

description: The utilization of immune-checkpoint inhibitors (ICIs) in cancer immunotherapy frequently leads to the occurrence of immune-related adverse events (irAEs), making it generally not recommended for patients with preexisting autoimmune diseases. Hence, we conducted a meta-analysis on safety and efficacy of ICIs in cancer patients with preexisting autoimmune diseases to provide further insights. PubMed, EMBASE, and Cochrane Library were systematically searched until December 20, 2024. The main summary measures used were pooled rate and risk ratio (RR) with 95% confidential interval (CI), which were analyzed using R statistic software. A total of 52 articles were included in the study. When cancer patients with preexisting autoimmune diseases received ICIs treatment, the overall incidence was 0.610 (95% CI: 0.531–0.686) for any grade irAEs, 0.295 (95% CI: 0.248–0.343) for flares, 0.325 (95% CI: 0.258–0.396) for de novo irAEs, 0.238 (95% CI: 0.174–0.309) for grade ≥3 irAEs, and 0.143 (95% CI: 0.109–0.180) for discontinuation due to immunotoxicity. Compared with those without autoimmune diseases, cancer patients with autoimmune diseases experienced a higher risk of any-grade irAEs (RR: 1.23, 95% CI: 1.12–1.35) and discontinuation due to immunotoxicity (1.40, 95% CI: 1.11–1.78). However, no statistically significant differences were observed in the incidence of grade ≥3 irAEs, objective response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS) between the two groups. During ICIs treatment, irAEs are common among cancer patients with autoimmune diseases, but severe irAEs is relatively low. ICIs are effective in this population, but should be strictly monitored when used to avoid immunotoxicity.
DOI: 10.6084/m9.figshare.29545036
title: Characterizing adolescent vaccination in publicly funded national immunization programs in Latin America and the Caribbean: A review of the literature

description: This review aimed to characterize adolescent vaccination schedules in publicly funded national immunization programs in Latin America and the Caribbean. The initial review identified vaccine type, target age and gender, dose schedule, and vaccination coverage rate (VCR) across 50 countries/territories in the region. A systematic review from January 2010–October 2023 was then conducted to identify primary data collection studies reporting VCRs. Overall, 42 webpages and 23 primary studies were identified. Among 47 countries/territories with ≥1 vaccine for adolescent immunization, human papillomavirus (HPV) vaccine was included in 45, tetanus component vaccines in 43, and meningococcal vaccines in 10. Catch-up vaccination for hepatitis B in 17, and yellow fever in all 13 endemic countries/territories. VCRs were primarily available for HPV. The findings of this review underscore the need to prioritize adolescent vaccination, improve accessibility, and strengthen tracking infrastructure to ensure comprehensive protection of this age group across the region.
DOI: 10.6084/m9.figshare.29545036.v1
title: Characterizing adolescent vaccination in publicly funded national immunization programs in Latin America and the Caribbean: A review of the literature

description: This review aimed to characterize adolescent vaccination schedules in publicly funded national immunization programs in Latin America and the Caribbean. The initial review identified vaccine type, target age and gender, dose schedule, and vaccination coverage rate (VCR) across 50 countries/territories in the region. A systematic review from January 2010–October 2023 was then conducted to identify primary data collection studies reporting VCRs. Overall, 42 webpages and 23 primary studies were identified. Among 47 countries/territories with ≥1 vaccine for adolescent immunization, human papillomavirus (HPV) vaccine was included in 45, tetanus component vaccines in 43, and meningococcal vaccines in 10. Catch-up vaccination for hepatitis B in 17, and yellow fever in all 13 endemic countries/territories. VCRs were primarily available for HPV. The findings of this review underscore the need to prioritize adolescent vaccination, improve accessibility, and strengthen tracking infrastructure to ensure comprehensive protection of this age group across the region.
DOI: 10.5281/zenodo.18711960
title: Lexical frequency data from DWDS corpora for a case study on regional variation in German

description: This dataset contains lexical frequency data from three DWDS corpora – the ZDL-Regionalkorpus, the Webmonitor-Korpus, and the Regionalliteratur-Korpus (not publicly accessible) – for a case study comparing the regional distribution of the following German nouns:



“Samstag” and “Sonnabend”,

“Komma” and “Beistrich”,

“Fahrrad”, “Radl”, and “Velo”,

“Aufzug”, “Fahrstuhl”, and “Lift”.


The dataset contains the following data types:



TXT files recording the corpus queries,

CSV tables with absolute and relative hit frequencies, obtained on 17 Feb. 2026 from the DWDS API,

SVG maps derived from the relative hit frequencies.
DOI: 10.6084/m9.figshare.29136805
title: T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine

description: This study reports the pre-clinical evaluation of peptides from EPV-CoV-19, a T cell epitope-based SARS-CoV-2 vaccine candidate, following spike-mRNA vaccination of a predominantly Hispanic American cohort. EPV-COV-19 peptides’ potential to boost T cell responses to spike protein vaccines was evaluated, confirming previously observed memory recall responses in donors with prior immunity to COVID-19. The vaccinated subjects’ averaged immune responses to the 15-peptide EPV-CoV-19 pool achieved 85% of the observed response to a spike protein peptide array containing a 7-fold greater epitope content, suggesting that the EPV-CoV-19 peptides have a higher relative concentration of T cell epitope content per-peptide. Ten of the 15 peptides contained spike epitopes conserved in the majority of variants of concern (VOC) evaluated over the 2020–2024 period. While commercial vaccines exhibited gradual loss of T cell epitope conservation with VOC over time, the EPV-CoV-19 epitope-peptides maintained conservation until the XBB variant emerged. The addition of one new peptide to the vaccine design reestablished broad T cell epitope coverage. These findings underscore the importance of identifying highly conserved T cell epitopes for vaccine designs that target rapidly-mutating strains of emergent pathogens, while also documenting broad memory T cell response to the vaccine in a predominantly Hispanic American cohort.